Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
XGN · NASDAQ · Services-Medical Laboratories
Exagen (XGN) · oqro.io/stocks/XGN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$4.13−0.28 (−6.35%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
13 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Nov 12 – Nov 13, 2026 · largest single transaction ~$509KNot reported under a pre-arranged trading plan
Nov 12, 2026~$509K · 109K sh @ $4.65
DetailsOfficial recordNov 13, 2026~$237K · 58K sh @ $4.08
DetailsOfficial recordTraded Nov 9 – Nov 11, 2026 · largest single transaction ~$373K
Nov 11, 2026~$373K · 71K sh @ $5.23
DetailsOfficial recordInsider selling
Traded Nov 6 · filed 5 days laterNot reported under a pre-arranged trading plan
Since the trade −28.9% · S&P 500 +2.6% · to Nov 13
A major shareholder of Exagen sold $69K of Exagen shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Oct 19 · filed 1 day later
Since the trade −44.4% · S&P 500 −1.6% · to Nov 13
A major shareholder of Exagen paid $104K out of pocket for Exagen shares. It was the first purchase in over a year.
John Aballi (President and CEO) sold ~$270K of Exagen
Automatic saleJeffrey G. Black (Chief Financial Officer) sold ~$149K of Exagen
Automatic saleJohn Aballi (President and CEO) sold ~$57K of Exagen
Automatic saleJohn Aballi (President and CEO) sold ~$41K of Exagen
Automatic saleJeffrey G. Black (Chief Financial Officer) sold ~$5.7K of Exagen
Automatic saleJohn Aballi (President and CEO) sold ~$376K of Exagen
Automatic saleJeffrey G. Black (Chief Financial Officer) sold ~$200K of Exagen
Automatic saleInsider selling
Traded Mar 25, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade +7.0% · S&P 500 +31.1% · to Nov 13
A major shareholder of Exagen sold $1.16M of Exagen shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Nov 20, 2024 · filed 7 days laterNot reported under a pre-arranged trading plan
Since the trade −1.7% · S&P 500 +27.8% · to Nov 13
A major shareholder of Exagen sold $660K of Exagen shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Nov 15, 2024 · filed 5 days later
Since the trade +38.6% · S&P 500 +28.8% · to Nov 13
The CFO of Exagen paid $66K out of pocket for Exagen shares. 1 other person at Exagen bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 14, 2024 · filed 4 days later
Since the trade +42.4% · S&P 500 +27.1% · to Nov 13
The CEO of Exagen paid $68K out of pocket for Exagen shares. 1 other person at Exagen bought some too, in the same month. It was the first purchase in over a year.
Nov 9, 2026~$54K · 8,500 sh @ $6.35
DetailsOfficial recordNov 10, 2026~$37K · 7,085 sh @ $5.26
DetailsOfficial record4 open-market purchases and 8 open-market sales by insiders of XGN between Feb 8, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 10, 2026. The data provider lists the next release for Mar 8, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 10, 2026 | 2 purchases, 2 sales | 1 purchase | 1 purchase, 2 sales |
| Aug 4, 2026 | None | None | 1 sale |
| May 11, 2026 | None | None | None |
| Mar 10, 2026 | 3 sales | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
